Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 205 to 213 of 213 entries
Sorted by: Best Match Show Resources per page
Available, Affordable, Accessible, Appealing: The A's of Influencing Healthy Eating and Active Living.

Delaware journal of public health

Eichinger M.
PMID: 34466875
Dela J Public Health. 2016 Dec 15;2(5):16-18. doi: 10.32481/djph.2016.12.006. eCollection 2016 Dec.

No abstract available.

Cite
Eichinger M. Available, Affordable, Accessible, Appealing: The A's of Influencing Healthy Eating and Active Living. Dela J Public Health. 2016;2(5):16-18doi: 10.32481/djph.2016.12.006.
Eichinger, M. (2016). Available, Affordable, Accessible, Appealing: The A's of Influencing Healthy Eating and Active Living. Delaware journal of public health, 2(5), 16-18. https://doi.org/10.32481/djph.2016.12.006
Eichinger, Michelle. "Available, Affordable, Accessible, Appealing: The A's of Influencing Healthy Eating and Active Living." Delaware journal of public health vol. 2,5 (2016): 16-18. doi: https://doi.org/10.32481/djph.2016.12.006
Eichinger M. Available, Affordable, Accessible, Appealing: The A's of Influencing Healthy Eating and Active Living. Dela J Public Health. 2016 Dec 15;2(5):16-18. doi: 10.32481/djph.2016.12.006. eCollection 2016 Dec. PMID: 34466875; PMCID: PMC8389783.
Copy Download .nbib Format: NLM
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Grahl S, Bussas M, Wiestler B, Eichinger P, Gaser C, Kirschke J, Zimmer C, Berthele A, Hemmer B, Mühlau M.
PMID: 34561843
Neurotherapeutics. 2021 Sep 24; doi: 10.1007/s13311-021-01118-2. Epub 2021 Sep 24.

Fingolimod and natalizumab are approved disease-modifying drugs in relapsing-remitting multiple sclerosis (RRMS). The two drugs have different modes of action and may therefore influence different aspects of MS-related tissue damage. In this retrospective cohort study, we longitudinally compared patients...

Cite
Grahl S, Bussas M, Wiestler B, et al. Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2021;doi: 10.1007/s13311-021-01118-2.
Grahl, S., Bussas, M., Wiestler, B., Eichinger, P., Gaser, C., Kirschke, J., Zimmer, C., Berthele, A., Hemmer, B., & Mühlau, M. (2021). Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, . https://doi.org/10.1007/s13311-021-01118-2
Grahl, S, et al. "Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis." Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. (2021). doi: https://doi.org/10.1007/s13311-021-01118-2
Grahl S, Bussas M, Wiestler B, Eichinger P, Gaser C, Kirschke J, Zimmer C, Berthele A, Hemmer B, Mühlau M. Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2021 Sep 24; doi: 10.1007/s13311-021-01118-2. Epub 2021 Sep 24. PMID: 34561843.
Copy Download .nbib Format: NLM
Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Schönbacher M, Aichinger N, Weidner L, Jungbauer C, Grabmer C, Schuha B, Rohde E, Mayr W, Körmöczi G.
PMID: 33976610
Transfus Med Hemother. 2021 Mar;48(2):99-108. doi: 10.1159/000509946. Epub 2020 Sep 23.

INTRODUCTION: Antibody-mediated transfusion-related acute lung injury (TRALI) is caused by antibodies against human leukocyte antigens (HLAs) or human neutrophil antigens (HNAs), and is one of the most serious complications associated with transfusion medicine. Prevention strategies like testing allo-exposed female...

Cite
Schönbacher M, Aichinger N, Weidner L, et al. Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience. Transfus Med Hemother. 2020;48(2):99-108doi: 10.1159/000509946.
Schönbacher, M., Aichinger, N., Weidner, L., Jungbauer, C., Grabmer, C., Schuha, B., Rohde, E., Mayr, W., & Körmöczi, G. (2021). Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 48(2), 99-108. https://doi.org/10.1159/000509946
Schönbacher, Marlies, et al. "Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 48,2 (2021): 99-108. doi: https://doi.org/10.1159/000509946
Schönbacher M, Aichinger N, Weidner L, Jungbauer C, Grabmer C, Schuha B, Rohde E, Mayr W, Körmöczi G. Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience. Transfus Med Hemother. 2021 Mar;48(2):99-108. doi: 10.1159/000509946. Epub 2020 Sep 23. PMID: 33976610; PMCID: PMC8077487.
Copy Download .nbib Format: NLM
The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders.

HemaSphere

Eichinger S, Morange PE, Cattaneo M, Fretigny M, Rauch A, van Hylckama Vlieg A, Trégouët DA, Ruf W, Levi M, Páramo JA, van der Poll T, Kyrle PA, Garagiola I, Peyvandi F.
PMID: 34522845
Hemasphere. 2021 Sep 10;5(10):e643. doi: 10.1097/HS9.0000000000000643. eCollection 2021 Oct.

No abstract available.

Cite
Eichinger S, Morange PE, Cattaneo M, et al. The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. Hemasphere. 2021;5(10):e643doi: 10.1097/HS9.0000000000000643.
Eichinger, S., Morange, P. E., Cattaneo, M., Fretigny, M., Rauch, A., van Hylckama Vlieg, A., Trégouët, D. A., Ruf, W., Levi, M., Páramo, J. A., van der Poll, T., Kyrle, P. A., Garagiola, I., & Peyvandi, F. (2021). The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. HemaSphere, 5(10), e643. https://doi.org/10.1097/HS9.0000000000000643
Eichinger, Sabine, et al. "The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders." HemaSphere vol. 5,10 (2021): e643. doi: https://doi.org/10.1097/HS9.0000000000000643
Eichinger S, Morange PE, Cattaneo M, Fretigny M, Rauch A, van Hylckama Vlieg A, Trégouët DA, Ruf W, Levi M, Páramo JA, van der Poll T, Kyrle PA, Garagiola I, Peyvandi F. The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. Hemasphere. 2021 Sep 10;5(10):e643. doi: 10.1097/HS9.0000000000000643. eCollection 2021 Oct. PMID: 34522845; PMCID: PMC8432639.
Copy Download .nbib Format: NLM
INR and not bilirubin levels predict postoperative morbidity in patients with malignant obstructive jaundice.

American journal of surgery

Scheufele F, Aichinger L, Jäger C, Demir IE, Schorn S, Demir E, Sargut M, Friess H, Ceyhan GO.
PMID: 34001332
Am J Surg. 2021 Nov;222(5):976-982. doi: 10.1016/j.amjsurg.2021.04.016. Epub 2021 May 12.

BACKGROUND: There are no established predictors for deciding between upfront surgery and PBD in pancreatic head malignancy. Once PBD is present, the ideal drainage-time remains elusive. The aim was, to identify predictors in jaundiced patients and ideal PBD-duration.METHODS: Analysis...

Cite
Scheufele F, Aichinger L, Jäger C, et al. INR and not bilirubin levels predict postoperative morbidity in patients with malignant obstructive jaundice. Am J Surg. 2021;222(5):976-982doi: 10.1016/j.amjsurg.2021.04.016.
Scheufele, F., Aichinger, L., Jäger, C., Demir, I. E., Schorn, S., Demir, E., Sargut, M., Friess, H., & Ceyhan, G. O. (2021). INR and not bilirubin levels predict postoperative morbidity in patients with malignant obstructive jaundice. American journal of surgery, 222(5), 976-982. https://doi.org/10.1016/j.amjsurg.2021.04.016
Scheufele, Florian, et al. "INR and not bilirubin levels predict postoperative morbidity in patients with malignant obstructive jaundice." American journal of surgery vol. 222,5 (2021): 976-982. doi: https://doi.org/10.1016/j.amjsurg.2021.04.016
Scheufele F, Aichinger L, Jäger C, Demir IE, Schorn S, Demir E, Sargut M, Friess H, Ceyhan GO. INR and not bilirubin levels predict postoperative morbidity in patients with malignant obstructive jaundice. Am J Surg. 2021 Nov;222(5):976-982. doi: 10.1016/j.amjsurg.2021.04.016. Epub 2021 May 12. PMID: 34001332.
Copy Download .nbib Format: NLM
A target fishing study to spot possible biological targets of fusaric acid: Inhibition of protein kinase-A and insights on the underpinning mechanisms.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association

Del Favero G, Aichinger G, Hohenbichler J, Marko D, Dall'Asta C, Dellafiora L.
PMID: 34748883
Food Chem Toxicol. 2021 Nov 05;112663. doi: 10.1016/j.fct.2021.112663. Epub 2021 Nov 05.

Fusaric acid is a secondary metabolite produced by various Fusarium fungi, present with relatively high incidence in Fusarium-contaminated foods. It was already described as phytotoxic and cytotoxic. However, the understanding of its molecular mechanisms is still fragmentary and further...

Cite
Del Favero G, Aichinger G, Hohenbichler J, et al. A target fishing study to spot possible biological targets of fusaric acid: Inhibition of protein kinase-A and insights on the underpinning mechanisms. Food Chem Toxicol. 2021;112663doi: 10.1016/j.fct.2021.112663.
Del Favero, G., Aichinger, G., Hohenbichler, J., Marko, D., Dall'Asta, C., & Dellafiora, L. (2021). A target fishing study to spot possible biological targets of fusaric acid: Inhibition of protein kinase-A and insights on the underpinning mechanisms. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 112663. https://doi.org/10.1016/j.fct.2021.112663
Del Favero, Giorgia, et al. "A target fishing study to spot possible biological targets of fusaric acid: Inhibition of protein kinase-A and insights on the underpinning mechanisms." Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association vol. (2021): 112663. doi: https://doi.org/10.1016/j.fct.2021.112663
Del Favero G, Aichinger G, Hohenbichler J, Marko D, Dall'Asta C, Dellafiora L. A target fishing study to spot possible biological targets of fusaric acid: Inhibition of protein kinase-A and insights on the underpinning mechanisms. Food Chem Toxicol. 2021 Nov 05;112663. doi: 10.1016/j.fct.2021.112663. Epub 2021 Nov 05. PMID: 34748883.
Copy Download .nbib Format: NLM
Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?.

Case reports in immunology

Steinlechner B, Kargl G, Schlömmer C, Holaubek C, Scheriau G, Eichinger S, Gratz J, Rössler B.
PMID: 34194852
Case Reports Immunol. 2021 Jun 04;2021:6624682. doi: 10.1155/2021/6624682. eCollection 2021.

Extracorporeal membrane oxygenation (ECMO) is often used in the management of COVID-19-related severe respiratory failure. We report the first case of a patient with COVID-19-related ARDS on ECMO support who developed symptoms of heparin-induced thrombocytopenia (HIT) in the absence...

Cite
Steinlechner B, Kargl G, Schlömmer C, et al. Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?. Case Reports Immunol. 2021;2021:6624682doi: 10.1155/2021/6624682.
Steinlechner, B., Kargl, G., Schlömmer, C., Holaubek, C., Scheriau, G., Eichinger, S., Gratz, J., & Rössler, B. (2021). Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?. Case reports in immunology, 20216624682. https://doi.org/10.1155/2021/6624682
Steinlechner, Barbara, et al. "Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?." Case reports in immunology vol. 2021 (2021): 6624682. doi: https://doi.org/10.1155/2021/6624682
Steinlechner B, Kargl G, Schlömmer C, Holaubek C, Scheriau G, Eichinger S, Gratz J, Rössler B. Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?. Case Reports Immunol. 2021 Jun 04;2021:6624682. doi: 10.1155/2021/6624682. eCollection 2021. PMID: 34194852; PMCID: PMC8184338.
Copy Download .nbib Format: NLM
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.

The Journal of clinical investigation

Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, Soto-Calderon H, Grajales L, Starr J, Andronov M, Mastellone M, Amonu C, Feret G, DeMarshall M, Buchanan M, Caturla M, Gordon J, Wanicur A, Monroy MA, Mampe F, Lindemuth E, Gouma S, Mullin AM, Barilla H, Pronina A, Irwin L, Thomas R, Eichinger RA, Demuth F, Luning Prak ET, Pascual JL, Short WR, Elovitz MA, Baron J, Meyer NJ, Degnan KO, Frank I, Hensley SE, Siegel DL, Tebas P.
PMID: 34788233
J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI155114.

BackgroundAntibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit in hospitalized patients with pneumonia are limited. Here, we...

Cite
Bar KJ, Shaw PA, Choi GH, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;131(24)doi: 10.1172/JCI155114.
Bar, K. J., Shaw, P. A., Choi, G. H., Aqui, N., Fesnak, A., Yang, J. B., Soto-Calderon, H., Grajales, L., Starr, J., Andronov, M., Mastellone, M., Amonu, C., Feret, G., DeMarshall, M., Buchanan, M., Caturla, M., Gordon, J., Wanicur, A., Monroy, M. A., Mampe, F., Lindemuth, E., Gouma, S., Mullin, A. M., Barilla, H., Pronina, A., Irwin, L., Thomas, R., Eichinger, R. A., Demuth, F., Luning Prak, E. T., Pascual, J. L., Short, W. R., Elovitz, M. A., Baron, J., Meyer, N. J., Degnan, K. O., Frank, I., Hensley, S. E., Siegel, D. L., & Tebas, P. (2021). A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. The Journal of clinical investigation, 131(24), . https://doi.org/10.1172/JCI155114
Bar, Katharine J, et al. "A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia." The Journal of clinical investigation vol. 131,24 (2021). doi: https://doi.org/10.1172/JCI155114
Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, Soto-Calderon H, Grajales L, Starr J, Andronov M, Mastellone M, Amonu C, Feret G, DeMarshall M, Buchanan M, Caturla M, Gordon J, Wanicur A, Monroy MA, Mampe F, Lindemuth E, Gouma S, Mullin AM, Barilla H, Pronina A, Irwin L, Thomas R, Eichinger RA, Demuth F, Luning Prak ET, Pascual JL, Short WR, Elovitz MA, Baron J, Meyer NJ, Degnan KO, Frank I, Hensley SE, Siegel DL, Tebas P. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI155114. PMID: 34788233.
Copy Download .nbib Format: NLM
Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension-procedural safety and system-related complications.

Pulmonary circulation

Steringer-Mascherbauer R, Lummersdorfer M, Függer R, Sigmund E, Huber C, Engleder D, Fröschl U, Aichinger J.
PMID: 33299542
Pulm Circ. 2020 Nov 30;10(4):2045894020970830. doi: 10.1177/2045894020970830. eCollection 2020.

Implantable pumps for intravenous treprostinil provide a promising option to overcome drawbacks of parenteral prostanoid administration with external pumps in pulmonary hypertension. We retrospectively analyzed 85 patients undergoing implantation in a single center since 2010. In our cohort, serious...

Cite
Steringer-Mascherbauer R, Lummersdorfer M, Függer R, et al. Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension-procedural safety and system-related complications. Pulm Circ. 2020;10(4):2045894020970830doi: 10.1177/2045894020970830.
Steringer-Mascherbauer, R., Lummersdorfer, M., Függer, R., Sigmund, E., Huber, C., Engleder, D., Fröschl, U., & Aichinger, J. (2020). Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension-procedural safety and system-related complications. Pulmonary circulation, 10(4), 2045894020970830. https://doi.org/10.1177/2045894020970830
Steringer-Mascherbauer, Regina, et al. "Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension-procedural safety and system-related complications." Pulmonary circulation vol. 10,4 (2020): 2045894020970830. doi: https://doi.org/10.1177/2045894020970830
Steringer-Mascherbauer R, Lummersdorfer M, Függer R, Sigmund E, Huber C, Engleder D, Fröschl U, Aichinger J. Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension-procedural safety and system-related complications. Pulm Circ. 2020 Nov 30;10(4):2045894020970830. doi: 10.1177/2045894020970830. eCollection 2020. PMID: 33299542; PMCID: PMC7711148.
Copy Download .nbib Format: NLM
Showing 205 to 213 of 213 entries